PAK2 and breast cancer: Together, these findings suggest that PAK2 could serve as a novel target to limit metastasis in breast cancer, and pharmacological PAK2 inhibitors such as FRAX597 could provide multiple therapeutic benefits, including limiting tumor progression, reducing metastasis and improving patient outcomes.